Portfolio

Alector’s mission is to develop therapies that empower the immune system to cure neuro-degeneration and cancer.

AM–Pharma is developing disease modifying Alkaline Phosphatase therapeutics.

ApoGen Biotechnologies is developing a new class of therapies that target key drivers of ongoing DNA mutation and tumor evolution.

Aquinnah Pharmaceuticals is developing small molecule therapeutics targeting persistent stress granules for the treatment of neurodegenerative disease.

Artios Pharma is developing cancer treatments that target DNA Damage Response pathways to selectively kill cancer cells.

Carisma Therapeutics is developing Chimeric Antigen Receptor-expressing macrophages to target and destroy solid tumors.

Disarm Therapeutics is creating disease-modifying therapeutics for patients with neurological diseases by directly treating axonal degeneration.

eFFECTOR Therapeutics is developing selective translation regulators as a new class of small molecule therapeutics for cancer and other serious diseases.

E-Scape Bio is developing therapeutics against genetic targets for neurodegenerative disease.

Jnana Therapeutics is building the first drug discovery platform dedicated to the solute carrier family of transporters.

Lodo Therapeutics is a drug discovery and development company focused on the creation of novel therapeutics derived from nature that will impact patients around the world.

Magnolia Neurosciences is developing potent and highly selective neuroprotective therapies.

Morphic Therapeutic is working to develop the first orally administered integrin therapeutics for patients with immunological, fibrotic, neoplastic, and vascular diseases.

PACT is developing personalized adoptive cell therapies based on neoantigen-targeted T cells against cancer.

Palleon Pharmaceuticals is targeting glycan-sensing checkpoints to unleash both the innate and adaptive immune responses to cancer.

Paragen Bio is a biotechnology company developing drugs for the treatment of autoimmune diseases.

Petra Pharma is dedicated to discovering and developing novel therapies that modulate phosphoinositide signaling pathways for the treatment of cancer and other serious diseases.

Prevail is developing disease-modifying gene therapies for patients with Parkinson’s disease and other neurodegenerative disorders.

Quentis is pioneering first in class immunotherapies that modulate endoplasmic reticulum stress response pathways in the tumor microenvironment.  

Rheostat is working to develop novel treatments for neurodegenerative disease through modulation of mitophagy and autophagy.

Ribometrix is a platform therapeutics company discovering small molecule drugs that target functional 3D RNA structures to treat human disease.

Ribon is dedicated to the discovery and development of first-in-class small molecule inhibitors to block cancer cells' fundamental ability to survive under stress.

Rodeo Therapeutics is a preclinical-stage biotech company focused on first in class small molecule modulators of prostaglandin biology for enhancing tissue repair and regeneration.

Tizona Therapeutics, Inc. is an immunology company harnessing the power of the immune system to develop treatments for cancer.